Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Isosorbide Mononitrate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.78 |
| ▸ | BCHE | P06276 | 6/20 | 0.58 |
| ▸ | GSR | P00390 | 7/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isosorbide Mononitrate SCHEMBL12787633 | 1.00 | MAPT (1.00) | MAPTALDH1A1BCHEGSRCA2 | |
| Isosorbide Mononitrate SCHEMBL5482432 | 1.00 | MAPT (1.00) | MAPTALDH1A1BCHEGSRCA2 | |
| Isosorbide Dinitrate SCHEMBL2138218 | 1.00 | MAPT (1.00) | MAPTALDH1A1BCHEGSRCA2 | |
| Isosorbide Mononitrate SCHEMBL616518 | 1.00 | MAPT (1.00) | MAPTALDH1A1BCHEGSRCA2 | |
| Isosorbide Mononitrate SCHEMBL12238510 | 1.00 | MAPT (1.00) | MAPTALDH1A1BCHEGSRCA2 | |
| Isosorbide Mononitrate SCHEMBL3056251 | 1.00 | MAPT (1.00) | MAPTALDH1A1BCHEGSRCA2 | |
| Isosorbide Mononitrate SCHEMBL23906861 | 1.00 | MAPT (1.00) | MAPTALDH1A1BCHEGSRCA2 | |
| Isosorbide Mononitrate SCHEMBL8893344 | 1.00 | MAPT (1.00) | MAPTALDH1A1BCHEGSRCA2 | |
| Isosorbide Mononitrate SCHEMBL8893635 | 1.00 | MAPT (1.00) | MAPTALDH1A1BCHEGSRCA2 | |
| Isosorbide Mononitrate SCHEMBL8894719 | 1.00 | MAPT (1.00) | MAPTALDH1A1BCHEGSRCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11779560-B2 | Methods of using nitric oxide donor compounds for treatment of COVID-19 and other infectious diseases | COEURATIVE, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20210346335-A1 | METHODS OF USING NITRIC OXIDE DONOR COMPOUNDS FOR TREATMENT OF COVID-19 AND OTHER INFECTIOUS DISEASES | COEURATIVE, INC. (US) | 2021-11-11 | — | — | US | disclosed |
| US-10913748-B2 | Compounds useful for treating cardiovascular diseases | COEURATIVE, INC. (US) | 2021-02-09 | — | — | US | disclosed |
| US-20200181161-A1 | NOVEL COMPOUNDS USEFUL FOR TREATING CARDIOVASCULAR DISEASES | COEURATIVE, INC. (US) | 2020-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10913748-B2 | Compounds useful for treating cardiovascular diseases | TNNI3, FABP3, TNNT2 | MAPT 4511/4885ALDH1A1 727/4885BCHE 1861/4885 |
| US-20200181161-A1 | NOVEL COMPOUNDS USEFUL FOR TREATING CARDIOVASCULAR DISEASES | FABP3, TNNI3, TNNT2 | MAPT 4649/4885ALDH1A1 1047/4885BCHE 3621/4885 |
| US-11779560-B2 | Methods of using nitric oxide donor compounds for treatment of COVID-19 and other infectious diseases | NOS2, NOS1, NOS3 | MAPT 3383/4885ALDH1A1 898/4885BCHE 680/4885 |
| US-20210346335-A1 | METHODS OF USING NITRIC OXIDE DONOR COMPOUNDS FOR TREATMENT OF COVID-19 AND OTHER INFECTIOUS DISEASES | NOS2, NOS1, NOS3 | MAPT 3383/4885ALDH1A1 898/4885BCHE 680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.